A large, multi-institution study led by a Brown University physician-scientist could have important implications for the development of new classes of cancer therapeutics.
Diabetes drugs may be doing more than managing blood sugar, they could also shape cancer biology in unexpected ways.
Cancer drug resistance is the devastating reason that treatments fail and cancers metastasize, spreading to distant sites ...
Varegacestat, a gamma secretase inhibitor, significantly improved progression-free survival while also meeting all key ...
In the high-stakes arena of cancer drug development, SU212 was engineered as a safer twist on podophyllotoxin—a toxic killer ...
Starton Holdings plans $40M IPO for cancer drug delivery innovations, but weak IP and limited backing make this a potentially ...
A new drug developed at UC Davis Health could provide a safer and more effective option for bladder cancer patients, reducing chemotherapy toxicity and potentially limiting the need for bladder ...
Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...
Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...
The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...
TipRanks on MSN
Vivesto shareholders approve heavily guaranteed rights issue to bolster cancer drug development
Vivesto AB ( ($SE:VIVE) ) has provided an update. Vivesto AB’s extraordinary general meeting on 22 December 2025 approved a major rights issue of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback